DSM completes Martek acquisition
Feb. 28, 2011
by Jeff Gelski
HEERLEN, THE NETHERLANDS — Royal DSM N.V. has completed its acquisition of Martek Biosciences Corp. Columbia, Md., for €790 million ($1,087 million), DSM said Feb. 28. The acquisition, first announced on Dec. 21, 2010, adds a new growth platform for healthy and natural food ingredients for infant formula and other food and beverage applications, especially those focused on polyunsaturated fatty acids such as microbial omega-3 fatty acid DHA (docosahexaenoic acid) and omega-6 fatty acid ARA (arachidonic acid).
An integration team consisting of both DSM and Martek representatives will assess the best way to combine the two organizations.